Werewolf Therapeutics (NASDAQ:HOWL) Price Target Lowered to $4.00 at JMP Securities

Werewolf Therapeutics (NASDAQ:HOWL) had its price objective lowered by stock analysts at JMP Securities from $12.00 to $4.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage currently has a “market outperform” rating on the stock. JMP Securities’ price objective would suggest a potential upside of 196.03% from the stock’s previous close.

Separately, HC Wainwright reiterated a “buy” rating and set a $15.00 target price on shares of Werewolf Therapeutics in a research report on Tuesday, November 19th.

Werewolf Therapeutics Stock Performance

NASDAQ HOWL opened at $1.35 on Tuesday. The stock has a market capitalization of $60.21 million, a price-to-earnings ratio of -0.88 and a beta of 0.38. The stock has a 50-day moving average of $1.76 and a 200 day moving average of $2.11. The company has a current ratio of 10.10, a quick ratio of 10.10 and a debt-to-equity ratio of 0.29. Werewolf Therapeutics has a twelve month low of $1.31 and a twelve month high of $8.19.

Institutional Investors Weigh In On Werewolf Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. SG Americas Securities LLC purchased a new position in Werewolf Therapeutics in the third quarter worth approximately $29,000. Point72 DIFC Ltd purchased a new position in Werewolf Therapeutics during the 2nd quarter valued at about $34,000. XTX Topco Ltd acquired a new position in Werewolf Therapeutics in the 3rd quarter valued at about $45,000. Rhumbline Advisers acquired a new stake in shares of Werewolf Therapeutics during the second quarter worth about $79,000. Finally, American Century Companies Inc. boosted its stake in shares of Werewolf Therapeutics by 50.7% in the second quarter. American Century Companies Inc. now owns 37,634 shares of the company’s stock valued at $92,000 after purchasing an additional 12,656 shares during the period. Institutional investors and hedge funds own 64.84% of the company’s stock.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.